Trial Search Results

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Progen Pharmaceuticals

Stanford Investigator(s):


  • Drug: PI-88
  • Drug: placebo


Phase 3


Key Inclusion Criteria:

   - Histologically-proven primary hepatocellular carcinoma with curative resection
   performed in the 4 - 6 weeks prior to randomisation.

   - ECOG performance status 0 to 2

   - Child Pugh classification A or B

Key Exclusion Criteria:

   - Any evidence of tumour metastasis or co-existing malignant disease

   - Any prior recurrence of HCC or any liver resection prior to the most recent procedure

   - History of prior HCC therapy

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kerry Hsieh
Not Recruiting